The U.S. multiple sclerosis drugs market size is calculated at USD 8.44 billion in 2025 and is forecasted to reach around USD 17.15 billion by 2034, accelerating at a CAGR of 8.18% from 2025 to 2034. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Multiple Sclerosis Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Multiple Sclerosis Drugs Market Revenue and Volume, by Drug Class
8.1.1 Immunomodulators
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Immunosuppressants
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Interferons
8.1.3.1. Market Revenue and Volume Forecast
8.1.4. Others
8.1.4.1. Market Revenue and Volume Forecast
9.1. U.S. Multiple Sclerosis Drugs Market Revenue and Volume, by Route of Administration
9.1.1. Oral
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Injection
9.1.2.1. Market Revenue and Volume Forecast
9.1.3. Intramuscular
9.1.3.1. Market Revenue and Volume Forecast
9.1.4. Intravenous
9.1.4.1. Market Revenue and Volume Forecast
9.1.5. Subcutaneous
9.1.5.1. Market Revenue and Volume Forecast
10.1. U.S. Multiple Sclerosis Drugs Market Revenue and Volume, by Distribution Channel
10.1.1. Hospital Pharmacies
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Retail Pharmacies
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Online Pharmacies
10.1.3.1. Market Revenue and Volume Forecast
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Drug Class
11.1.4.2. Market Revenue and Volume Forecast, by Route of Administration
11.1.4.3. Market Revenue and Volume Forecast, by Distribution Channel
12.1. AbbVie Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Pfizer
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Biogen
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. TG Therapeutics
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Genentech (Roche)
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Kyverna Therapeutics, Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Immunic Therapeutics
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Zenas BioPharma, Inc
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample